COMP <GO>
RGEN vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Repligen Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: RGEN 3
— JNJ 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: RGEN
LAST: $176.94 (-6.20%) • MKT CAP: $10.69B
options-implied-move
7.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
options-implied-move
7.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.20% | 67.90% | +20.30 | RGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | 25.50% | -23.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 18.5x | +76.50 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | 2.97% | -2.09 | JNJ | /fcf-yield <GO> |
| Operating Margin | 1.80% | 34.70% | -32.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 1.60% | 28.50% | -26.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 6.00% | -9.30 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 5.59 | +3.72 | RGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.00% | 7.20% | -0.20 | RGEN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 60.4 | -11.69 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.08 | -0.04 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 23.0x | +117.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.69B | $662.49B | -$651.80B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | JNJ REV | RGEN GROSS % | JNJ GROSS % | RGEN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | $93.9M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | $149.7M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | $113.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
JNJ // BETA 1.08